INTRODUCTION
============

Type 2 diabetes mellitus (T2DM) has reached to a pandemic level and is currently a significant challenge to health care system worldwide. More than 60% of the world\'s population with diabetes comes from Asia and the incidence of T2DM in Asia is increasing more rapidly than the rest of the world \[[@B1]\]. Unlike in the West, where older population is most affected, the burden of diabetes in Asian countries is disproportionately high in young to middle-age adults. The incidence of diabetic nephropathy is alarmingly high in patients with early onset T2DM, especially in those with poor glycemic control \[[@B2]\]. In Asia, most of newly diagnosed end-stage renal disease patients are due to T2DM. How to control this chronic and debilitating disease is currently a very important health issue in Asia. Unfortunately, current medical treatment has been relatively unsatisfactory as more than half of the patients cannot achieve the therapeutic goal \[[@B3][@B4]\]. Those with poorly controlled T2DM are exposed to high risk of developing microvascular and macrovascular complications such as blindness, limb amputation, end-stage renal disease, and cardiovascular accidents. It also carries a heavy burden of psychosocial and health-economic consequences. Recently, a potential cure for diabetes, bariatric surgery, has arisen in an unexpected way. Bariatric surgery, a weight reduction surgery, has been shown not only an effective treatment for severe obesity (body mass index \[BMI\] \>35 kg/m^2^) but also result in marked improvement of T2DM control \[[@B5]\]. In addition to weight loss, many mechanisms, including calorie restriction, improved β-cell function, improved insulin sensitivity, alterations in gut physiology, bile acid metabolism, and gut microbiota may contribute in T2DM remission after metabolic surgery \[[@B6]\]. Therefore, gastrointestinal metabolic surgery recently has been proposed as a new treatment modality for obesity related T2DM in patients with BMI \<35 kg/m^2^ \[[@B7]\]. Although bariatric surgery was introduced in Asia later than the Western countries and relatively less well established, the use of bariatric surgery to treat T2DM is pioneered from this region as Asia is in the epicenter of T2DM epidemic. This review summarized the development of metabolic surgery and the current evidences on efficacy of metabolic surgery to treat T2DM in Asia over the past decade. This review will build a foundation for metabolic surgery and the development of further clinical trials to provide more evidence in metabolic surgery for the treatment of T2DM.

HISTORY
=======

The initiation of metabolic surgery started from the report by Pories et al. \[[@B8]\] in 1995. In this landmark paper, the authors reported that gastric bypass is the most effective therapy for T2DM in morbidly obese patients. Rubino and Marescaux \[[@B9]\], then, rejuvenated the metabolic surgery by publishing the provoke concept of duodenum exclusion by an elaborate animal experiment in 2004. In Asia, Lee et al. \[[@B10]\] published the first paper in the world to report the effectiveness of bariatric surgery on the treatment of metabolic syndrome in 2004. Lee et al. \[[@B11]\] then published the first two reports about the efficacy of bariatric surgery on T2DM treatment in Asian in 2008 and 2009. However, Asian Pacific Metabolic and Bariatric Surgery Society was the first society to propose using bariatric/metabolic surgery for T2DM treatment and recommended to set the indication for metabolic surgery at lower BMI \<32 kg/m^2^ in 2005 \[[@B7]\]. The first randomized controlled trial (RCT) in the world specific to metabolic surgery is from Asia \[[@B12]\]. This study compared laparoscopic sleeve gastrectomy (LSG) to laparoscopic gastric bypass (LGB) for the treatment of T2DM in Asian patients with BMI \<35 kg/m^2^ and was the first study to prove that LGB (a duodenum exclusion procedure) had better efficacy on T2DM remission than LSG (non-duodenum exclusion procedure). Following this landmark study, many reports, clinical trials, and researches had come out from this region and contributed to the development of metabolic surgery. After many Asian societies advocated new consensus of using metabolic surgery to treat T2DM for Asians, the international society incorporated the new consensus for Asian \[[@B13]\]. At this time, metabolic surgery has been formally put into the algorithm of T2DM treatment.

EFFICACY OF DIFFERENT METABOLIC PROCEDURES
==========================================

Bariatric surgery has been evolving over the past 50 years. There have been numerous surgical approaches to weight loss surgery. The application of laparoscopic techniques to bariatric surgery in the past decade has reduced perioperative morbidity and has contributed to a remarkable increase in popularity of bariatric surgery and metabolic surgery for the treatment of T2DM. Among all the procedures, LSG, LGB, and adjustable gastric banding were the three most commonly performed bariatric/metabolic procedures in Asia ([Fig. 1](#F1){ref-type="fig"}) \[[@B14]\].

Laparoscopic sleeve gastrectomy
-------------------------------

LSG removes approximately 75% of the stomach from greater curvature side and leave a long narrow gastric tube and antrum. This procedure not only restricts the food intake but also increases both gastric emptying and intestinal transit time. Because of the relative simplicity, good weight result and less long-term nutritional problems, LSG becomes the most commonly performed bariatric/metabolic surgery worldwide nowaday \[[@B14]\]. The first report of using LSG to treat T2DM was from India \[[@B15]\]. The remission rate of T2DM (glycosylated hemoglobin \<6.5% without antidiabetic medications) 1 year after LSG was 96.2%. However, the remission rate decreased to 50% in patients with BMI \<30 kg/m^2^ \[[@B16]\]. Many reports have been published from different areas of Asia \[[@B17][@B18][@B19][@B20][@B21][@B22][@B23][@B24][@B25][@B26][@B27][@B28][@B29][@B30]\]. [Table 1](#T1){ref-type="table"} summarizes the reported T2DM remission rate according to different criteria and follow-up years. The remission rate was higher in high BMI group but a trend of decreasing glycemic control with increasing follow-up duration was observed. The advantages of LSG were its efficacy, relative simplicity, less long-term malnutrition, less complication and avoidance of remnant gastric cancer. It does not require insertion of foreign body and avoids band related complications. However, two randomized trials reported that the overall glycemic control was better in LGB over LSG for T2DM treatment in low BMI patients, possibly due to the duodenum exclusion effect \[[@B4][@B12]\]. A meta-analysis also supported the superiority of LGB over LSG for T2DM treatment \[[@B31]\]. Therefore, all the T2DM patients should receive detailed evaluation and counselling before receiving metabolic surgery.

Laparoscopic gastric bypass
---------------------------

Five-decades old gastric bypass surgery has become a time honored procedure and is currently regarded as a standard bariatric/metabolic procedure. Following the introduction of laparoscopic era, LGB has accelerated the development both of the bariatric and metabolic surgery \[[@B32]\]. LGB isolates a small gastric pouch from the rest of the stomach. The ingested food in the small gastric pouch was then channeled into the distal part of small bowel via an anastomosis. Thus, the gastric bypass procedure (1) restricts the food and calorie intake, (2) bypasses the gut hormone rich duodenum and proximal jejunum, and (3) expedites the undigested food to the distal intestine, stimulating glucagon-like peptide-1 (GLP-1) and peptide-YY (PYY) secretion, as well altering the gut microbiota environment and bile acid metabolism \[[@B6]\]. The drainage procedure is by either Roux-en-Y gastric bypass (RYGB) or a simplified loop bypass, single anastomosis (mini-) gastric bypass (SAGB) \[[@B33]\]. The first report of gastric bypass for the treatment of T2DM in Asian was from Lee et al. \[[@B11]\] in 2008. The authors reported a very high T2DM remission rate of more than 80% after SAGB in those with BMI \>35, but remission rate decreased to 75% in those with BMI \<35. Since then, there have been reports about LGB for T2DM treatment from many areas of Asia \[[@B34][@B35][@B36],[@B37][@B38][@B39][@B40][@B41][@B42][@B43]\]. [Table 2](#T2){ref-type="table"} summarized the reported T2DM remission after gastric bypass according to different criteria and follow-up years. The remission rate was higher in high BMI group. A decreasing trend of glycemic control along with the increasing follow-up years was observed again. However, in general, the remission rate after LGB was higher than that of LSG.

Laparoscopic adjustable gastric banding
---------------------------------------

Laparoscopic adjustable gastric banding (LAGB) is the safest bariatric surgical procedure but the efficacy is less favored than other bariatric procedures. Although some randomized trial had shown the better efficacy of LAGB for the treatment of T2DM compared to medical treatment, LAGB is now rarely performed in Asia because of its unpredictability in outcome \[[@B17][@B18][@B30]\]. The reported T2DM remission rate after LAGB was only 26.3%, less significant than the 58.3% in LSG \[[@B30]\], and around 80% in gastric bypass \[[@B17][@B18]\].

NEW BARIATRIC/METABOLIC PROCEDURES
==================================

Laparoscopic duodenal-jejunal bypass surgery was inspired from Rubino\'s animal experiment \[[@B21]\]. However, simple exclusion of duodenum was found to be less effective than conventional bariatric/metabolic surgery \[[@B44]\]. Therefore, duodenojejunal bypass with sleeve gastrectomy (DJB-SG) has recently been introduced from this region as a novel metabolic surgery by adding a duodenal switch procedure to SG, which combines the principles and advantages of SG and duodenal switch \[[@B45]\]. The efficacy of DJB-SG was similar to convention gastric bypass \[[@B46]\]. Although gastric bypass is the standard metabolic surgery, gastric bypass had a major problem of precluding the screening of excluded stomach. This may raise a great concern in Asian countries with high incidence of gastric cancer. Therefore, the major advantage of DJB-SG compared to RYGB is avoidance of the risk of gastric cancer arising from remnant stomach by leaving no excluded stomach. Other theoretical advantage of DJB-SG is related to the preservation of the pylorus, which include the prevention of dumping syndrome and facilitating the iron, calcium, vitamin B12, and protein absorption by preserving the acid and intrinsic factor. A recent study showed that by adding a duodenal exclusion to SG, the DJB-SG can increase 10% more weight loss and improve the glycemic control as well as reduce the uric acid level \[[@B47]\]. This finding further supported the important role of duodenum exclusion in the treatment of T2DM. A 5-year report was published recently from Japan to support the efficacy of this procedure \[[@B48]\].

Other novel procedure, such as ileal transportation \[[@B49]\] or proximal jejunal bypass were either too complicated or without evidence to support in clinical usage.

EFFICACY OF METABOLIC SURGERY IN ASIANS IN CONTRAST TO NON-ASIAN POPULATION
===========================================================================

Several studies in Asian and Western population have supported unequivocal advantage of metabolic surgery over life style modification and intensive medical treatment alone in terms of diabetes remission ([Table 3](#T3){ref-type="table"}) \[[@B3],[@B4],[@B40],[@B50],[@B51],[@B52],[@B53],[@B54]\]. The outcomes of metabolic surgery on T2DM remission was comparable between Asians and Western populations. T2DM remission was reported around 40% to 75% following metabolic surgery in contrast to poor remission rate in non-surgical group which was reported around 0% to 10% in both Asian and non-Asian populations. Even though the follow-up period in most of the published studies were short; only 1 to 2 years, T2DM resolution following metabolic surgery is very promising. More reports on longer term metabolic outcomes are expected to come out in near future to provide stronger evidences on durability of metabolic effects of bariatric surgery.

RANDOMIZED CONTROL TRIALS
=========================

Six RCTs about metabolic surgery had been published from Asia \[[@B3][@B12][@B17][@B25][@B28][@B29]\]. [Table 4](#T4){ref-type="table"} listed the detail of each studies. Two focused on the comparison of bariatric surgery and best medical treatment for the treatment of T2DM \[[@B3][@B17]\]. One study recruited 120 patients with BMI between 30 to 40 from Taiwan and USA \[[@B3]\]. Among those patients, 71 patients were mild obesity (BMI 30 to 35 kg/m^2^), 35 participants (19 USA and 16 Taiwanese) enrolled in medical treatment group, where 36 participants (22 USA and 12 Taiwanese) enrolled RYGB. The other study recruited 120 patients with BMI \>28 kg/m^2^ T2DM patients with hypertension into three groups \[[@B17]\]. Both groups achieved significantly better glycemic control and reduction of hypertension medication in surgical treatment comparing to medical treatment.

The other three studies focused on the comparison of LSG and LGB for the treatment of T2DM \[[@B12][@B25][@B28]\]. One studies found that SAGB is better than LSG in control low BMI patients \[[@B12]\]. The other two studies found similar efficacy between RYGB and LSG in the treatment of T2DM \[[@B17][@B28]\]. One RCT compared cost effectiveness between LSG and RYGB with 2-year follow-up \[[@B29]\]. The author concluded that LSG is as effective as RYGB and is slightly more cost-effective than RYGB. Another two on-going studies are awaiting to be published.

MECHANISM OF EFFECT
===================

Overwhelming evidence have supported that effective diabetes resolution was achieved in obese T2DM patients after undergoing metabolic surgery. The underlying mechanism for diabetes remission after metabolic surgery is intriguing. Initially, four possible mechanisms had been proposed, including the starvation followed by weight-loss hypothesis, the ghrelin hypothesis, the lower intestinal (hind-gut) hypothesis, and the upper intestinal (fore-gut) hypothesis. More theories were proposed recently \[[@B13]\]. None of these theories necessarily precludes the others. Therefore, any combination of these mechanisms may contribute to some degree in T2DM remission and it is very difficult to design a study to elucidate the exact mechanism.

Although Asian tends to accumulate fat in abdomen and develop T2DM relatively at a younger age, lower BMI and much higher incidence \[[@B1][@B2]\], metabolic surgery still works very well in Asian. A rapid reduction of insulin resistance and recovery of early insulin secretion have been documented after both LSG and LGB \[[@B16]\]. However, the recovery of incretin effect was found to be higher in LGB than LSG \[[@B24]\]. This discrepancy was attributed to different level of gut hormone and cytokine secretion \[[@B55]\]. It has been suggested that the dramatic reduction in ghrelin after SG may explain the weight loss mechanism. In addition to the dramatic reduction of ghrelin effect, SG was also reported to have hind-gut effect with increasing of GLP-1 and PYY due to increasing transit time after SG \[[@B55]\]. It was also reported that weight loss to be similar between GB and SG but duodenum exclusion do play a role in T2DM remission \[[@B12][@B47]\].

OPERATIVE RISKS AND LONGTERM NUTRITIONAL EFFECTS
================================================

Although the safety of bariatric/metabolic surgery had been improved significantly recently, metabolic surgery still carried a major complication rate of 2% with a mortality rate 0.2% \[[@B31]\]. Once major complication occurred, the severity was usually higher in those with T2DM because of the associated medical conditions. Therefore, detailed preoperative cardiovascular, renal, and ophthalmologic evaluation is mandatory for T2DM patients before receiving metabolic surgery. Metabolic surgery should also be performed by experienced surgeons and in high volume center to reduce the surgical risk and maximize the outcome.

Along with weight reduction and T2DM remission, metabolic surgery may also bring some side-effects and long-term nutritional problems \[[@B3][@B56]\]. A certain degree of malnutrition commonly accompanies the food restriction and duodenum exclusion, including the iron, calcium, vitamin B12, and protein deficiency. Therefore, T2DM patients with metabolic surgery should be regularly followed up, monitored and treated by a multidisciplinary team. Routine vitamin and minor element supplements are also indicated after metabolic surgery.

PREDICTORS OF DIABETES REMISSION AND PATIENT SELECTION
======================================================

Optimal outcomes for diabetes remission after metabolic surgery can be achieved if patients best suited to the surgery are selected and those who will predictably have a poor result are excluded. To be able to make such decisions, we need some predictors and guideline from Asia for the Asian. This information is helpful for applying metabolic surgery for T2DM treatment in clinical practice.

Current indications for bariatric surgery were based on BMI and metabolic surgery was recommended for T2DM Asian with BMI \>27.5 kg/m^2^ \[[@B11]\]. Although T2DM remission is closely associated with BMI, many other factors, such as abdominal obesity, β-cell function, duration of disease, and age are all important predictor of T2DM remission after metabolic surgery in Asian.

Since T2DM is a progressive disease with continuously depleting β-cell function, the longer the duration of T2DM, the poorer the response to T2DM is expected. Patients with long history of diabetes usually have poor β-cell function and not suitable for metabolic surgery as they may be taking unnecessary surgical risks without achieving desirable remission. Therefore, current international guideline recommends metabolic surgery should be performed as earlier as possible. Metabolic surgery is now recommended as a priority treatment of choice for severely obese (BMI \>32.5 for Asian) T2DM patients.

Metabolic surgery is indicated in those with acceptable β-cell function and C-peptide is recommended for a useful tool to evaluate T2DM patient for metabolic surgery \[[@B57]\]. C-peptide is a connecting peptide to insulin. Pro-insulin is formed by one C-peptide molecule attached to each insulin molecule. Pro-insulin splits into insulin and C-peptide after it is release from the pancreas into the blood in response to a rise in blood glucose. C-peptide is a valuable test in the classifying different types of diabetes. Therefore, C-peptide levels in T2DM patients may reflect the status of pancreas islet cell preservation and predict the success of surgical treatment of T2DM.

Age is also an important consideration for metabolic surgery. The incidence of young-onset T2DM is high in Asians. As these patients tend to have severe disease and more complications, metabolic surgery is especially worth in this group of patients. A recent study showed that young onset (\<40 years age) T2DM Asian had more severe disease than late onset T2DM patients but had a better response to metabolic surgery \[[@B58]\]. This study highlighted the importance of metabolic surgery to be considered as priority for those Asian with young onset and poorly controlled T2DM.

To combine those important predictors, a scoring system has recently been developed \[[@B59]\]. This ABCD Diabetes Surgery Score system consisted of four variables; age, BMI, C-peptide level, and duration of diabetes. A 4-point score ranging from 0 (lowest value) to 3 (maximal value) was used for BMI, C-peptide level, and duration of diabetes. For age, only a one-point score was used. The summated ABCD score ranges from 0 to 10 points. The higher the score, the higher the chance of T2DM remission after metabolic surgery can be expected. Young patients with high BMI, short duration of disease, and good β-cell function are associated with high ABCD score. ABCD score is especially designed for predicting the success of metabolic surgery and has been validated in many studies \[[@B60]\]. In clinical practice, this score system can help the endocrinologist to set the priority for referring patients for metabolic surgery and the surgeon to counsel the patients for metabolic surgery and choice of surgical procedure.

CONCLUSIONS
===========

The success of bariatric surgery in obese diabetic individuals (BMI \>35 kg/m^2^) has led to the paradigm shift of metabolic surgery for the treatment of T2DM, including patients with a BMI \<35 kg/m^2^. Data from Asian studies supported that metabolic surgery is the promising therapy for glycemic control in poorly controlled Asian T2DM patients with BMI \>27.5 kg/m^2^. The mechanisms of metabolic gastrointestinal surgery are thought to be dependent on the dramatic enterohormonal changes after physioanatomical re-arrangement of the gastrointestinal tract. Right selection of patients and metabolic surgery procedure is paramount importance to achieve high T2DM remission and successful outcomes after surgery. Further researches are required to establish new guidelines and indications for metabolic surgery in less obese or lean patients. How to provide a safe bariatric surgery, train qualified bariatric surgeon and continue to develop better techniques will be the important issues in surgical treatment of obesity in future.
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###### Type 2 diabetes mellitus outcomes after laparoscopic sleeve gastrectomy in Asian (by BMI and follow-up time)
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  Study                                Case no.   Age, yr     BMI, kg/m^2^   Duration of T2DM, yr   HbA1c, %   T2DM remission rate (HbA1c),%   Follow-up, yr          
  ------------------------------------ ---------- ----------- -------------- ---------------------- ---------- ------------------------------- --------------- ------ ---
  Lee et al. (2010) \[[@B16]\]         20         45.0±10.8   28.5±3.3       7.9±5.1                9.3±0.8    \-                              50              \-     1
  Lee et al. (2011) \[[@B12]\]         30         45          30.3           NR                     10.0       \-                              47              \-     1
  Park et al. (2015) \[[@B20]\]        11         35.8±10.2   32.7±1.6       NR                     8.0        \-                              \-              82     1
  Lee et al. (2016) \[[@B22]\]         109        43.2±11.0   35.7±7.2       3.3±3.5                8.8±1.5    \-                              \-              56     1
  Liu et al. (2015) \[[@B19]\]         65         40.9±10.0   40.6±6.2       4.5                    8.2±1.8    80.9                            34.5            34.5   1
  Lee et al. (2012) \[[@B18]\]         20         44.4±11.9   40.7±6.6       NR                     9.1±1.2    \-                              72.7            \-     1
  Lakdawala et al. (2011) \[[@B21]\]   14         27          42             NR                     NR         78.6                            \-              \-     1
  Park et al. (2015) \[[@B20]\]        143        32.2±9.3    42.6±6.6       NR                     7.1        \-                              \-              83     1
  Shah et al. (2010) \[[@B15]\]        53         46.5±8.7    45.2±9.3       4.2±5.0                8.4±1.6    \-                              96.2            \-     1
  Kasama et al. (2008) \[[@B17]\]      6          38±10       49.1±10        NR                     NR         88.9                            \-              \-     1
  Tang et al. (2016) \[[@B29]\]        34         36.6±8.0    38.4±8.6       5.1±4.1                7.4±1.8    \-                              76.5            50     2
  Wong et al. (2012) \[[@B30]\]        24         NR          40±6.7         5.9±6.4                7.9±2.4    85.7                            71.4            58.3   2
  Yang et al. (2015) \[[@B28]\]        32         40.4±9.4    31.8±3.0       4.0±1.7                8.5±1.2    \-                              89.3            78.6   3
  Liu et al. (2015) \[[@B19]\]         39         40.9±10.0   40.6±6.2       4.5                    8.2±1.8    74.2                            52.7            47.2   3
  Todkar et al. (2010) \[[@B23]\]      23         44.6±11.9   40.7±6.6       NR                     NR         \-                              72.7            \-     3
  Lee et al. (2014) \[[@B24]\]         30         46.4±8.1    31.0±2.8       6.9±5.3                9.9±1.8    \-                              36.7            6.7    5
  Jammu et al. (2016) \[[@B27]\]       23         23          35             NR                     NR         \-                              56.5            \-     5
  Lee et al. (2016) \[[@B22]\]         109        43.2±4.0    35.7±7.2       33±3.5                 3.8±1.5    \-                              \-              56     5
  Zhang et al. (2014) \[[@B25]\]       9          29.3±9.8    38.5±4.2       NR                     9.1±1.2    \-                              67              \-     5
  Liu et al. (2015) \[[@B19]\]         19         40.9±10.0   40.6±6.2       4.5                    8.2±1.8    78.6                            70.6            64.7   5
  Kular et al. (2014) \[[@B26]\]       61         NR          42±5.2         NR                     NR         81                              \-              \-     5

Values are presented as mean±standard deviation.

BMI, body mass index; T2DM, type 2 diabetes mellitus; HbA1c, glycosylated hemoglobin; NR, not reported.

###### Type 2 diabetes mellitus outcomes after gastric bypass in Asian (by BMI and follow-up time)
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  Study                                Case no.   Age, yr     BMI, kg/m^2^   Duration of T2DM, yr   HbA1c, %   T2DM remission rate (HbA1c),%   Follow-up, yr          
  ------------------------------------ ---------- ----------- -------------- ---------------------- ---------- ------------------------------- --------------- ------ ------
  Kim et al. (2011) \[[@B33]\]         10         46.9        27.2           6.6                    9.7        60                              \-              \-     0.5
  Shah et al. (2010) \[[@B34]\]        15         45.6±12.0   28.9±4.0       8.7±5.3                10.1±2.0   \-                              100             \-     0.75
  Malapan et al. (2014) \[[@B35]\]     29         53          24.4±1.8       5.5                    10±1.8     \-                              37.9            \-     1
  Liang et al. (2015) \[[@B43]\]       86         48.5        24.7±2.1       8.6±2.0                6.8±4.0    \-                              \-              23.3   1
  Kim et al. (2014) \[[@B36]\]         172        46±11       25.3±3.2       9.6±5.2                9.0±1.7    53                              \-              \-     1
  Dixon et al. (2013) \[[@B37]\]       103        47.5±9.6    26.0±3.0       7.1±1.6                9.1±1.6    67                              \-              30.1   1
  Zhu et al. (2012) \[[@B38]\]         30         48.2±8.2    26.2±3.6       6.0±4.5                8.0±1.8    \-                              30              \-     1
  Lee et al. (2011) \[[@B12]\]         30         44.6±8.6    30.2±2.2       5.8±5.7                10.0±1.8   \-                              93              \-     1
  Huang et al. (2011) \[[@B39]\]       22         47.4±11.2   30.8±3.2       9.2                    6.6±6.3    90.9                            \-              63.6   1
  Liang et al. (2013) \[[@B40]\]       31         50.8±5.4    30.5±0.9       2.4±1.7                10.5±1.2   \-                              90              \-     1
  Lakdawala et al. (2013) \[[@B42]\]   52         49          32.6           8.4                    8.8        96.2                            73.1            \-     1
  Dixon et al. (2013) \[[@B41]\]       154        39.5±10.7   37.2±8.8       2.0                    9.1±1.7    88                              69.5            \-     1
  Park et al. (2015) \[[@B20]\]        134        42.3±11.1   37.9±5.2       4.6±5.8                8.0±1.5    \-                              61.8            46.1   1
  Kim et al. (2011) \[[@B33]\]         116        46±11       25.3±3.2       9.6±5.2                9.0±1.7    63                              \-              \-     2
  Ikramuddin et al. (2016) \[[@B3]\]   14         45.7±7.9    31.9±1.7       6.1±3.6                9.6±1.1    86                              57              29     2
  Tang et al. (2016) \[[@B29]\]        38         40.4±12.3   37.8±5.6       6.5±4.1                7.4±1.8    \-                              57.9            36.8   2
  Yang et al. (2015) \[[@B28]\]        32         41.4±9.3    32.3±2.4       4.2±1.9                8.9±1.3    \-                              92.6            85.2   3
  Lee et al. (2014) \[[@B24]\]         30         44.6±8.6    30.2±2.2       5.8±5.7                10.0±1.8   \-                              60.0            26.7   5
  Lee et al. (2016) \[[@B22]\]         470        41.8±10.9   36.9±7.2       4.5±4.8                8.6±1.7    \-                              \-              63.8   5
  Zhang et al. (2014) \[[@B25]\]       8          32.2        39.3±3.8       NR                     NR         87.5                            \-              \-     5
  Lakdawala et al. (2013) \[[@B42]\]   52         49          32.6           8.4                    8.8        96.2                            57.7            \-     5
  Kular et al. (2014) \[[@B26]\]       63         NR          44±3.1         NR                     NR         92                              \-              \-     5
  Jammu et al. (2016) \[[@B27]\]       95         42          50             NR                     NR         \-                              88.4            \-     5

Values are presented as mean±standard deviation.

BMI, body mass index; T2DM, type 2 diabetes mellitus; HbA1c, glycosylated hemoglobin; NR, not reported.

###### Type 2 diabetes mellitus remission of bariatric surgery versus medical treatment in Asian and non-Asian populations
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  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                Study recruitment year   Country          Study type                   Intervention (*n*)                                                    Patients                                   Follow-up duration   Outcomes on DM remission
  ------------------------------------ ------------------------ ---------------- ---------------------------- --------------------------------------------------------------------- ------------------------------------------ -------------------- -----------------------------------------------------------------------------------------------------------
  Ikramuddin et al. (2016) \[[@B3]\]   2008--2011               Taiwan and USA   RCT                          Medical (16)\                                                         T2DM with BMI 30--35 kg/m^2^               2 yr                 DM remission: 0% vs. 90%
                                                                                                              RYGB (14)                                                                                                                             

  Liang et al. (2013) \[[@B40]\]       2008--2011               China            RCT                          Usual care (36)\                                                      T2DM with BMI \>28 kg/m^2^                 1 yr                 DM remission: 0% vs. 0% vs. 57%
                                                                                                              Exenatide (34)\                                                                                                                       
                                                                                                              RYGB (31)                                                                                                                             

  Palikhe et al. (2014) \[[@B50]\]     2011--2012               India            RCT                          Intensive Medical therapy(17)\                                        T2DM with BMI ≥27.5 kg/m^2^                1 yr                 DM resolution: 0% vs. 39%
                                                                                                              LSG (14)                                                                                                                              

  Heo et al. (2012) \[[@B54]\]         2008--2011               Korea            Retrospective cohort study   Weight control medication and lifestyle modification therapy (224)\   Obese patients with or without comorbids   18 mo                DM resolution: 10% vs. 57%
                                                                                                              Bariatric surgery (261)                                                                                                               

  Cummings et al. (2016) \[[@B51]\]    2011--2012               USA              RCT                          ILMI (20)\                                                            T2DM with BMI \<35 kg/m^2^                 1 yr                 Diabetes remission: 5.9% vs. 60.0%
                                                                                                              RYGB (23)                                                                                                                             

  Mingrone et al. (2015) \[[@B52]\]    2009                     Italy            RCT                          Medical treatment (20)\                                               T2DM with BMI ≥35 kg/m^2^                  5 yr                 Diabetes remission at 5 years: 0% vs. 37% vs. 63%\
                                                                                                              RYGB (20)\                                                                                                                            Relapse of hyperglycaemia in patients who achieved 2 year remission: RYGB (53%) vs. BPD (37%)
                                                                                                              Biliopancreatic diversion (20)                                                                                                        

  Schauer et al. (2014) \[[@B4]\]      2007--2011               USA              RCT                          Intensive medical therapy alone (50)\                                 T2DM with BMI 27--43 kg/m^2^               1 yr                 DM remission: 12% vs. 42% vs. 37%
                                                                                                              RYGB (50)\                                                                                                                            
                                                                                                              LSG (50)                                                                                                                              

  Ikramuddin et al. (2016) \[[@B3]\]   2008--2010               USA              RCT                          LS/IMM (60)\                                                          T2DM with BMI 30--39.9 kg/m^2^             1 yr                 Achieved primary composite end point (HbA1c \<7.0%, LDL-C \<100 mg/dL, and SBP \<130 mm Hg): 19% vs. 49%\
                                                                                                              RYGB (60)                                                                                                                             HbA1c \<7.0%: 32% vs. 75%

  Dixon et al. (2008) \[[@B53]\]       2006--2008               Australia        RCT                          Medical/conventional (30)\                                            T2DM with BMI\                             2 yr                 DM remission: 13% vs. 73%
                                                                                                              LAGB (30)                                                             \>30 to \<40 kg/m^2^                                            
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

DM, diabetes mellitus; RCT, randomized controlled trial; RYGB, Roux-en-Y gastric bypass; T2DM, type 2 diabetes mellitus; BMI, body mass index; LSG, laparoscopic sleeve gastrectomy; ILMI, intensive lifestyle and medical intervention; BPD, biliopancreatic diversion; LS/IMM, lifestyle modification and intensive medical management; HbA1c, glycosylated hemoglobin; LDL-C, low density lipoprotein cholesterol; SBP, systolic blood pressure; LAGB, laparoscopic adjustable gastric banding.

###### Randomized trials on metabolic surgery in Asia
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  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                Year         Country          Patients                       Follow-up duration, yr   Intervention (*n*)   Outcomes                                                  Conclusion
  ------------------------------------ ------------ ---------------- ------------------------------ ------------------------ -------------------- --------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------
  Lee et al. (2011) \[[@B12]\]         2007--2008   Taiwan           T2DM with BMI 25--35 kg/m^2^   5                        LSG (30)\            DM remission 30% vs. 60%\                                 SAGB was more likely to achieve better glycemic control than SG
                                                                                                                             SAGB(30)             Similar weight loss\                                      
                                                                                                                                                  SAGB group had a higher incretin effect than the SG       

  Ikramuddin et al. (2016) \[[@B3]\]   2008--2011   Taiwan and USA   T2DM with BMI 30--35 kg/m^2^   2                        Medical (16)\        DM remission 0% vs. 0% vs. 90%\                           RYGB was more likely to achieve better glycemic control than medical treatment in both Taiwanese and American mild obese subjects with T2DM
                                                                                                                             RYGB (14)            Better weight loss in RYGB                                

  Kasama et al. (2008) \[[@B17]\]      2008--2011   China            T2DM with BMI \>28 kg/m^2^     1                        Usual care (36)\     DM remission 0% vs. 57%\                                  RYGB improves a number of parameters including cardiovascular function in obese hypertensive people with T2DM
                                                                                                                             Exenatide (34)\      Significant decrease in hypertension medication in RYGB   
                                                                                                                             RYGB (31)                                                                      

  Yang et al. (2015) \[[@B28]\]        2009--2014   China            T2DM with BMI 28--35 kg/m^2^   3                        LSG (32)\            DM remission 78.6% vs. 85.2% had %EWL 92.3% vs. 81.9%\    SG had similar positive effects on diabetes and dyslipidemia compared to RYGB
                                                                                                                             RYGB (32)            Similar improvement in serum lipids                       

  Tang et al. (2016) \[[@B29]\]        2011--2013   China            T2DM with BMI \>28 kg/m^2^     2                        LSG (34)\            DM remission is comparable 50% vs. 36.8%\                 LSG is a cost-effective intervention for managing T2DM
                                                                                                                             RYGB (38)            Similar weight loss: cost-effectiveness                   
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

T2DM, type 2 diabetes mellitus; BMI, body mass index; LSG, laparoscopic sleeve gastrectomy; SAGB, single anastomosis gastric bypass; DM, diabetes mellitus; SG, sleeve gastrectomy; RYGB, Roux-en-Y gastric bypass; EWL, excess weight loss.
